Publication:
Scleral necrosis after plaque radiotherapy of uveal melanoma: A case-control study

dc.contributor.authorSwathi Kalikien_US
dc.contributor.authorCarol L. Shieldsen_US
dc.contributor.authorDuangnate Rojanapornen_US
dc.contributor.authorJosep Badalen_US
dc.contributor.authorLaxmi Devisettyen_US
dc.contributor.authorJacqueline Emrichen_US
dc.contributor.authorLydia Komarnickyen_US
dc.contributor.authorJerry A. Shieldsen_US
dc.contributor.otherThomas Jefferson Universityen_US
dc.contributor.otherL.V. Prasad Eye Institute Indiaen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherDrexel Universityen_US
dc.date.accessioned2018-10-19T05:26:07Z
dc.date.available2018-10-19T05:26:07Z
dc.date.issued2013-05-01en_US
dc.description.abstractPurpose: To identify risk factors and outcome of scleral necrosis after plaque radiotherapy of uveal melanoma. Design: Case-control study. Participants: A total of 73 cases with scleral necrosis and 73 controls without necrosis after plaque radiotherapy. Controls were matched for anteroposterior tumor epicenter and follow-up duration. Intervention: Plaque radiotherapy with iodine-125, cobalt-60, iridium-192, or ruthenium-106. Main Outcome Measures: Scleral necrosis. Results: Of 5057 patients treated with plaque radiotherapy for uveal melanoma, 73 (1%) developed radiotherapy-induced scleral necrosis. Scleral necrosis occurred in <1% of patients (3/1140) when plaque radiotherapy was used for tumors <3 mm in thickness, 1% of patients (33/3155) with 3- to 8-mm tumor thickness, and 5% of patients (37/762) with >8-mm-thick tumors. On the basis of tumor location, scleral necrosis was detected after plaque radiotherapy of iris melanoma in 0% of patients (0/91), ciliary body melanoma in 29% of patients (67/235), and choroid melanoma in <1% of patients (6/4731). The mean time interval between plaque radiotherapy and scleral necrosis was 32 months (median, 23 months; range, 4-126 months). The mean basal dimension of scleral necrosis was 4 mm (median, 3 mm; range, 1-15 mm), equivalent to 29% of mean tumor base (median, 24%; range, 6%-100%) and 22% of mean plaque size (median, 19%; range, 5%-75%). Multivariate analysis of factors that predicted clinically evident scleral necrosis included ciliary body (P = 0.0001) and pars plana to ora serrata (P < 0.0001) locations of anterior tumor margin, tumor thickness ≥6 mm (P = 0.0001), and radiation dose ≥400 Gy to the outer sclera (P = 0.0455). Scleral necrosis remained stable in 48% of patients (35/73), increased in size/severity in 48% of patients (35/73), or progressed to scleral perforation in 4% of patients (3/73) over a mean follow-up of 79 months (median, 54 months; range, 5-351 months). Treatment of scleral necrosis included observation in 81% of patients (59/73), scleral patch graft in 14% of patients (10/73), and enucleation in 5% of patients (4/73). Conclusions: Scleral necrosis after plaque radiotherapy of uveal melanoma was detected in 1% of cases. Factors predictive of scleral necrosis included increasing tumor thickness, ciliary body and peripheral choroidal location, and higher radiation dose to sclera. Most patients (81%) did not require treatment, and 4% evolved to full-thickness perforation. © 2013 American Academy of Ophthalmology.en_US
dc.identifier.citationOphthalmology. Vol.120, No.5 (2013), 1004-1011en_US
dc.identifier.doi10.1016/j.ophtha.2012.10.021en_US
dc.identifier.issn15494713en_US
dc.identifier.issn01616420en_US
dc.identifier.other2-s2.0-84877745683en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/32375
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84877745683&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleScleral necrosis after plaque radiotherapy of uveal melanoma: A case-control studyen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84877745683&origin=inwarden_US

Files

Collections